Blood-Based ctDNA Monitoring Outperforms Imaging for Immunotherapy

The research, conducted in collaboration with the Allegheny Health Network Cancer Institute, analyzed 142 patients across 12 solid tumor types. Findings indicate that molecular monitoring acts as a dominant independent predictor of survival, with a hazard ratio of 5.3. When integrated with traditional radiographic review, the predictive power increases significantly, reaching a hazard ratio of 13.8 at landmark assessment and 19.7 with continued monitoring.

Beyond clear-cut cases, the assay addresses a frequent clinical ambiguity where patients show stable disease on imaging despite underlying progression. In these instances, the molecular data provides actionable insights that standard scans miss. Furthermore, the study highlights the necessity of serial testing; one in four patients exhibited a molecular rebound pattern—a temporary decline in tumor signals followed by a rise—which a single blood draw would fail to capture. This longitudinal approach allows oncologists to bypass the limitations of single-timepoint snapshots, providing a more dynamic view of how a patient’s disease responds to therapy over time.